Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers

Hanna M. Romanska , Piotr Potemski , Magdalena Krakowska , Magdalena Mieszkowska , Shalini Chaudhri , Radzisław Kordek , Robert Kubiak , Valerie Speirs , Andrew M. Hanby , Rafał Sądej , Fedor Berditchevski

Abstract

Background: The proposed involvement of CD151 in breast cancer (BCa) progression is based on findings from studies in invasive ductal carcinoma (IDC). The IDC and invasive lobular carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical significance of CD151 alone and in association with integrin α3β1 in patients with ILC in context of the data of our recent IDC study. Methods: Expression of CD151 and/or integrin α3β1 was evaluated in ILC samples (N=117) using immunohistochemistry. The findings were analysed in relation to our results from an IDC cohort (N=182) demonstrating a prognostic value of an expression of CD151/integrin α3β1 complex in patients with HER2-negative tumours. Results: Unlike in the IDCs, neither CD151 nor CD151/α3β1 complex showed any correlation with any of the ILC characteristics. Lack of both CD151 and α3β1 was significantly correlated with poor survival (P=0.034) in lymph node-negative ILC N(−) cases. The CD151−/α3β1− patients had 3.12-fold higher risk of death from BCa in comparison with the rest of the ILC N(−) patients. Conclusions: Biological role of CD151/α3β1 varies between ILC and IDC. Assessment of CD151/α3β1 might help to identify ILC N(−) patients with increased risk of distant metastases.
Author Hanna M. Romanska
Hanna M. Romanska,,
-
, Piotr Potemski
Piotr Potemski,,
-
, Magdalena Krakowska
Magdalena Krakowska,,
-
, Magdalena Mieszkowska (IFB)
Magdalena Mieszkowska,,
- Intercollegiate Faculty of Biotechnology UG
, Shalini Chaudhri
Shalini Chaudhri,,
-
, Radzisław Kordek
Radzisław Kordek,,
-
, Robert Kubiak
Robert Kubiak,,
-
, Valerie Speirs
Valerie Speirs,,
-
, Andrew M. Hanby
Andrew M. Hanby,,
-
, Rafał Sądej (IFB / DMedB)
Rafał Sądej,,
- Department of Medical Biotechnology
et al.`
Journal seriesBritish Journal of Cancer, ISSN 0007-0920, (A 40 pkt)
Issue year2015
Vol113
No9
Pages1350-1357
Publication size in sheets0.5
DOIDOI:10.1038/bjc.2015.344
URL https://doi.org/10.1038/bjc.2015.344
Languageen angielski
LicenseOther; published final; Uznanie Autorstwa - Użycie Niekomercyjne - Na tych samych warunkach (CC-BY-NC-SA); after publication
Score (nominal)40
ScoreMinisterial score = 40.0, 20-12-2017, ArticleFromJournal
Ministerial score (2013-2016) = 40.0, 20-12-2017, ArticleFromJournal
Publication indicators WoS Impact Factor: 2015 = 5.569 (2) - 2015=5.617 (5)
Citation count*
Cite
Share Share

Get link to the record


* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.
Back